Related Experiment Video
Updated: Mar 2, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Dendritic cell vaccines and obstacles to beneficial immunity in glioma patients
Christopher J Wheeler1, Keith L Black
1Maxine Dunitz Neurosurgical Institute, Medical Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. wheelerc@cshs.org
Abstract:
The dismal prognoses suffered by malignant primary brain tumor (glioma) patients remain unchanged over the past two decades, despite significant improvements in the treatment of distinct tumors. Dendritic cell-based vaccine therapies represent a promising experimental approach to treat malignant gliomas, but major challenges still remain to render vaccination more effective. These challenges include diminishing the risk of pathological autoimmunity, identifying the cellular basis of clinical vaccine benefits and increasing the proportion of patients experiencing such benefits. Over the past three years, studies in glioma patients have characterized tumor antigens on human gliomas, identified some of the immune cells involved in beneficial anti-glioma immunity and examined how gliomas may be altered by sub-lethal immune influences, providing a glimpse of the strength with which immunity influences glioma clinical outcome. This progress promises to improve clinical vaccines for glioma, and perhaps for other cancers.
Insights
Dendritic cell vaccines show promise for malignant glioma treatment, but challenges like autoimmunity and identifying immune benefits persist. Recent research advances understanding of immune influences on glioma, paving the way for improved cancer vaccines.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Vaccines
Background:
- Malignant primary brain tumors (gliomas) have poor prognoses with limited treatment advancements over 20 years.
- Dendritic cell-based vaccines are a promising experimental therapy for malignant gliomas.
- Key challenges include managing autoimmunity, understanding immune mechanisms of benefit, and increasing patient response rates.
Purpose of the Study:
- To review recent progress in understanding the immune system's role in glioma.
- To identify advancements that could enhance dendritic cell vaccine efficacy for gliomas.
- To explore how immunity influences glioma clinical outcomes.
Main Methods:
- Characterization of tumor antigens in human gliomas.
- Identification of immune cells involved in anti-glioma immunity.
- Examination of glioma response to sub-lethal immune influences.
Main Results:
- Tumor antigens on human gliomas have been identified.
- Key immune cells contributing to beneficial anti-glioma immunity have been recognized.
- Insights into how gliomas are affected by immune system interactions have been gained.
Conclusions:
- Recent research provides a foundation for improving dendritic cell vaccines for glioma.
- Understanding immune influences on glioma is crucial for therapeutic advancements.
- These findings may also inform vaccine development for other cancer types.
Related Concept Videos
01:40Cell-mediated Immune Responses
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy